Company
Headquarters: Taipei City, Taiwan
TW$4.47 Billion
TWD as of Jan. 1, 2025
US$136.1 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $622.07 B |
Vertex Pharmaceuticals Incorporated | $113.24 B |
CSL Limited | $95.75 B |
Regeneron Pharmaceuticals, Inc. | $76.33 B |
Marinomed Biotech AG | $56.13 B |
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
BioGend Therapeutics Co., Ltd. develops regenerative bio-orthopaedic products. The company is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. BioGend Therapeutics Co., Ltd. was founded in 2016 and is based in Taipei, Taiwan.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
BioGend Therapeutics Co. Ltd has the following listings and related stock indices.
Stock: TWSE: 6733 wb_incandescent